ImmusanT Expands Platform to Type 1 Diabetes with Investment from JDRF T1D Fund
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep 11, 2018--ImmusanT, Inc., a clinical stage company that is leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to translate and deliver first-in-class peptide-based immune therapies to people living with autoimmune diseases, today announced that it has received an investment from the JDRF T1D Fund, a venture philanthropy fund exclusively devoted to finding and funding the best type 1 diabetes (T1D) commercial opportunities. The funding marks the JDRF T1D Fund’s first direct investment in ImmusanT and in peptide immunotherapy, an approach that has the potential to positively alter the immune response involved in multiple autoimmune diseases. Terms of the financing were not disclosed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180911005174/en/
With the funds, ImmusanT plans to accelerate the translation of insights and clinical experience gained from its celiac disease program to the development of a novel vaccine candidate for T1D. The company’s lead candidate, Nexvax2®, a peptide-based therapeutic vaccine, has demonstrated safety and relevant bioactivity in multiple Phase 1 studies for celiac disease, an-HLA associated disease with many similarities to T1D.
“This is an exciting time for ImmusanT as we expand the application of our ESIT platform beyond celiac disease to advance the development of a vaccine for type 1 diabetes, a disease for which there is significant unmet medical need,” said Leslie Williams, Chief Executive Officer of ImmusanT. “With the support of the JDRF T1D Fund, we are optimistic that we have the right resources to advance our technology and positively impact the lives of those living with this debilitating disease.”
“We believe ImmusanT’s platform could deliver a transformative therapy for T1D, along with a better understanding of the antigens that are driving this disease,” said Jonathan Behr, Managing Director at the JDRF T1D Fund. “We will support the company beyond our capital investment, collaborating to ensure ImmusanT has the highest chance of success.”
To learn more about ImmusanT’s efforts in T1D and its collaboration with the JDRF T1D Fund, visit www.immusant.com/t1d.
About ImmusanT, Inc. At ImmusanT, we are developing a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Our Epitope-Specific Immuno-Therapy™ (ESIT™) platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. Our lead program, Nexvax2®, is in clinical development with the goal of protecting celiac disease patients against the debilitating effects of gluten. www.ImmusanT.com
About JDRF T1D Fund The JDRF T1D Fund ( www.t1dfund.org ) is a venture philanthropy fund accelerating life-changing solutions to treat, prevent and cure type 1 diabetes (T1D) through catalytic commercial investments. Through its investments in partnership with private capital, including venture capital, corporations and foundations, the T1D Fund seeks to attract the private investment necessary to advance drugs, devices, diagnostics, and vaccines into the hands of those living with T1D. The T1D Fund invests in areas strategically aligned with JDRF, the leading global organization funding T1D research, with an exclusive focus on supporting the best commercial opportunities. The T1D Fund will reinvest any realized gains into new investments to further its mission.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180911005174/en/
CONTACT: MacDougall Biomedical Communications
George E. MacDougall, 781-235-3060
JDRF T1D Fund
Amy Montalto, 617-910-7542
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL
SOURCE: ImmusanT, Inc.
Copyright Business Wire 2018.
PUB: 09/11/2018 08:00 AM/DISC: 09/11/2018 08:01 AM